MX390159B - Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada. - Google Patents
Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada.Info
- Publication number
- MX390159B MX390159B MX2015012879A MX2015012879A MX390159B MX 390159 B MX390159 B MX 390159B MX 2015012879 A MX2015012879 A MX 2015012879A MX 2015012879 A MX2015012879 A MX 2015012879A MX 390159 B MX390159 B MX 390159B
- Authority
- MX
- Mexico
- Prior art keywords
- neostx
- bupivacaine
- combination
- epinephrine
- neosaxitoxin
- Prior art date
Links
- PPEKGEBBBBNZKS-HGRQIUPRSA-N neosaxitoxin Chemical compound N=C1N(O)[C@@H](COC(=O)N)[C@@H]2NC(=N)N[C@@]22C(O)(O)CCN21 PPEKGEBBBBNZKS-HGRQIUPRSA-N 0.000 title abstract 4
- PPEKGEBBBBNZKS-UHFFFAOYSA-N Neosaxitoxin Natural products N=C1N(O)C(COC(=O)N)C2N=C(N)NC22C(O)(O)CCN21 PPEKGEBBBBNZKS-UHFFFAOYSA-N 0.000 title abstract 2
- 238000002690 local anesthesia Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000002035 prolonged effect Effects 0.000 title abstract 2
- 229960003150 bupivacaine Drugs 0.000 abstract 3
- 229960005139 epinephrine Drugs 0.000 abstract 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 abstract 2
- 229930182837 (R)-adrenaline Natural products 0.000 abstract 2
- 239000003195 sodium channel blocking agent Substances 0.000 abstract 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 229940125794 sodium channel blocker Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Rheumatology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Debido a que los bloqueadores de los canales de sodio que actúan sobre el sitio 1 presentan una actividad única y no pueden usarse para extrapolar la dosis eficaz de otros bloqueadores de los canales de sodio que actúan sobre el sitio 1, se realizaron estudios para identificar las dosis de la neosaxitoxina ("NeoSTX") y de la bupivacaina, por sí sola o en combinación con epinefrina, que podrían resultar eficaces para aliviar el dolor durante un período de dos ó tres días en los seres humanos. Las combinaciones de bupivacaina y NeoSTX provocaron un bloqueo con una confiabilidad y una duración mayores que las que se observaron cuando se administró la NeoSTX sola. Con una combinación de tres compuestos, NeoSTX, bupivacaína y epinefrina, se obtuvo una anestesia local más prolongada que la que se obtuvo con una combinación de dos compuestos, NeoSTX y bupivacaína. La adición de epinefrina a la combinación de NeoSTX y bupivacaína tuvo como consecuencia una prolongación dramática en la duración del bloqueo completo ante los estímulos mecánicos. Sobre la base de estos resultados, se desarrollaron diversas formulaciones de dosificación combinadas específicas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361789054P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/030372 WO2014145580A1 (en) | 2013-03-15 | 2014-03-17 | Neosaxitoxin combination formulations for prolonged local anesthesia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015012879A MX2015012879A (es) | 2016-06-24 |
| MX390159B true MX390159B (es) | 2025-03-20 |
Family
ID=50549480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012879A MX390159B (es) | 2013-03-15 | 2014-03-17 | Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada. |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10314833B2 (es) |
| EP (2) | EP3492075B1 (es) |
| JP (1) | JP6313420B2 (es) |
| KR (4) | KR102787826B1 (es) |
| CN (1) | CN105142625B (es) |
| AU (2) | AU2014232881B2 (es) |
| CA (2) | CA2906851C (es) |
| CL (1) | CL2015002534A1 (es) |
| CY (1) | CY1121606T1 (es) |
| DK (1) | DK2968225T3 (es) |
| ES (2) | ES2727292T3 (es) |
| HR (1) | HRP20190419T1 (es) |
| HU (1) | HUE042711T2 (es) |
| IL (1) | IL241346B (es) |
| LT (1) | LT2968225T (es) |
| MX (1) | MX390159B (es) |
| NZ (1) | NZ710890A (es) |
| PE (1) | PE20160011A1 (es) |
| PL (2) | PL2968225T3 (es) |
| PT (1) | PT2968225T (es) |
| RS (1) | RS58750B1 (es) |
| RU (2) | RU2015143665A (es) |
| SI (1) | SI2968225T1 (es) |
| TR (1) | TR201903411T4 (es) |
| WO (1) | WO2014145580A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6313420B2 (ja) * | 2013-03-15 | 2018-04-18 | ザ チルドレンズ メディカル センター コーポレイション | 持続する局所麻酔のためのネオサキシトキシン併用製剤 |
| WO2016100209A1 (en) | 2014-12-15 | 2016-06-23 | The Children's Medical Center Corporation | Non-toxic topical anesthetic ophthalmic compositions |
| EP3359134B1 (en) | 2015-10-08 | 2025-04-09 | The Children's Medical Center Corporation | Compositions and compositions for use in on-demand high-efficiency triggerable anesthesia |
| US10117847B2 (en) * | 2015-12-04 | 2018-11-06 | Ventis Pharma | Extended duration local anesthetic formulation |
| US10791651B2 (en) | 2016-05-31 | 2020-09-29 | Carbice Corporation | Carbon nanotube-based thermal interface materials and methods of making and using thereof |
| CA3084034C (en) * | 2017-12-01 | 2022-08-16 | The Chilren's Medical Center Corporation | Covalent anesthetic-polymer conjugates for prolonged local anesthesia |
| RU2701571C1 (ru) * | 2019-02-13 | 2019-09-30 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ профилактики болевого синдрома после вмешательств на коленном суставе |
| US20230052318A1 (en) * | 2020-01-06 | 2023-02-16 | Pacira Pharmaceuticals, Inc. | Treatment of pain associated with cesarean section surgery with sustained-release liposomal anesthetic compositions |
| US20230080593A1 (en) | 2020-01-10 | 2023-03-16 | Pacira Pharmaceuticals, Inc. | Treatment of pain by subarachnoid administration of sustained-release liposomal anesthetic compositions |
| CN115515581A (zh) | 2020-01-10 | 2022-12-23 | 帕西拉制药股份有限公司 | 通过给予缓释脂质体麻醉组合物治疗疼痛 |
| WO2022150708A1 (en) | 2021-01-11 | 2022-07-14 | Pacira Pharmaceuticals, Inc. | Treatment of hip pain with sustained-release liposomal anesthetic compositions |
| CN117320696A (zh) | 2021-03-19 | 2023-12-29 | 帕西拉制药股份有限公司 | 通过给予缓释脂质体麻醉组合物治疗儿科患者的疼痛 |
| US12226610B2 (en) | 2022-11-03 | 2025-02-18 | Pacira Pharmaceuticals, Inc. | Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions |
| US11918565B1 (en) | 2022-11-03 | 2024-03-05 | Pacira Pharmaceuticals, Inc. | Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions |
| WO2024151854A1 (en) * | 2023-01-13 | 2024-07-18 | Smilanich Michael D | Composition for local anesthesia and uses thereof |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3004894A (en) | 1959-04-07 | 1961-10-17 | Upjohn Co | Therapeutic composition comprising tetracycline and a dioxolane |
| US3328259A (en) | 1964-01-08 | 1967-06-27 | Parachem Corp | Dressing for a wound containing a hemostatic agent and method of treating a wound |
| US3374144A (en) | 1965-10-07 | 1968-03-19 | Miles Lab | Ophthalmic composition |
| SE391286B (sv) | 1971-01-26 | 1977-02-14 | Astra Pharma Prod | Forfarande for framstellning av en lokalanestetiskt verksam injektionslosning med forlengd varaktighet av verkan |
| US3957996A (en) | 1971-12-08 | 1976-05-18 | Astra Pharmaceutical Products, Inc. | Pharmaceutical local anesthetic compositions |
| US3966934A (en) | 1971-12-08 | 1976-06-29 | Astra Pharmaceutical Products, Inc. | Synergistic local anesthetic compositions |
| US4029793A (en) | 1973-06-12 | 1977-06-14 | Astra Pharmaceutical Products, Inc. | Synergistic local anesthetic compositions |
| US4029794A (en) | 1973-06-12 | 1977-06-14 | Astra Pharmaceutical Products, Inc. | Pharmaceutical local anesthetic composition |
| US4001413A (en) | 1973-06-12 | 1977-01-04 | Astra Pharmaceutical Products, Inc. | Pharmaceutical local anesthetic composition employing saxitoxin |
| US4022899A (en) | 1973-06-12 | 1977-05-10 | Astra Pharmaceutical Products, Inc. | Synergistic local anesthetic compositions |
| CA1165240A (en) | 1980-07-09 | 1984-04-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
| US4313958A (en) | 1980-10-24 | 1982-02-02 | The Procter & Gamble Company | Method of producing analgesia |
| US4443473A (en) | 1981-06-30 | 1984-04-17 | The Procter & Gamble Company | Carbamate derivatives |
| US4401663A (en) | 1981-06-30 | 1983-08-30 | The Procter & Gamble Company | Novel sulfonamide derivatives |
| US4460602A (en) | 1981-06-30 | 1984-07-17 | The Procter & Gamble Company | Urea derivatives |
| US4537776A (en) | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
| US4544669A (en) | 1983-07-14 | 1985-10-01 | The Procter & Gamble Company | Compounds and compositions useful for producing analgesia |
| US4544668A (en) | 1983-07-14 | 1985-10-01 | The Procter & Gamble Company | Compounds and compositions useful for producing analgesia |
| US4564633A (en) | 1983-07-14 | 1986-01-14 | The Procter & Gamble Company | Compositions and methods useful for producing analgesia |
| US4493848A (en) | 1983-07-14 | 1985-01-15 | The Procter & Gamble Company | Compositions and methods useful for producing analgesia |
| US4605670A (en) | 1984-02-01 | 1986-08-12 | Nitto Electric Industrial Co., Ltd. | Method for percutaneously administering metoclopramide |
| CA1274508A (en) | 1984-05-31 | 1990-09-25 | Imre Szilagyi | Primycin components and process for the separation of the antibiotic complex |
| US4654323A (en) | 1984-11-13 | 1987-03-31 | Bar Ilan University | Method and composition for the therapeutic and prophylactic treatment of trauma to the skin |
| US5013759A (en) | 1985-06-10 | 1991-05-07 | The Procter & Gamble Company | Compounds and compositions having anti-inflammatory and analgesic activity |
| US4863970A (en) | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
| US5006342A (en) | 1986-12-22 | 1991-04-09 | Cygnus Corporation | Resilient transdermal drug delivery device |
| US5099030A (en) | 1987-03-09 | 1992-03-24 | The Procter & Gamble Company | Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain |
| US5045565A (en) | 1987-03-09 | 1991-09-03 | The Procter & Gamble Company | Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain |
| US4820720A (en) | 1987-08-24 | 1989-04-11 | Alza Corporation | Transdermal drug composition with dual permeation enhancers |
| US5871472A (en) | 1987-11-17 | 1999-02-16 | Brown University Research Foundation | Planting devices for the focal release of neuroinhibitory compounds |
| US5008289A (en) | 1988-12-02 | 1991-04-16 | Galenpharma, Inc. | Composition for treating nasal disorders and headaches |
| US4997853A (en) | 1988-12-02 | 1991-03-05 | Galenpharma, Inc. | Method and compositions utilizing capsaicin as an external analgesic |
| US5134166A (en) | 1988-12-02 | 1992-07-28 | Genderm Corporation | Method for treating nasal disorders and headaches |
| US4973468A (en) | 1989-03-22 | 1990-11-27 | Cygnus Research Corporation | Skin permeation enhancer compositions |
| AU3326493A (en) | 1991-12-16 | 1993-07-19 | Alza Corporation | Improved formulations with hydrophobic permeation enhancers |
| DK0659073T3 (da) | 1992-09-10 | 2002-03-11 | Childrens Medical Center | Bionedbrydelige polymermatrixer med vedvarerende afgivelse af lokalanæstetika |
| US5700485A (en) | 1992-09-10 | 1997-12-23 | Children's Medical Center Corporation | Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid |
| US5576016A (en) | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
| WO1995024903A1 (en) | 1994-03-17 | 1995-09-21 | Nanning Maple Leaf Pharmaceutical Co., Ltd. | The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence |
| HUP9700322A3 (en) | 1995-06-09 | 2001-03-28 | Euro Celtique Sa | Formulations and methods for providing prolonged local anesthesia |
| US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
| WO1998043619A2 (en) | 1997-04-02 | 1998-10-08 | The Regents Of The University Of California | Method of local anesthesia |
| US6326020B1 (en) | 1997-05-16 | 2001-12-04 | Children's Medical Center Corporation | Local anesthetic formulations |
| US7016870B1 (en) | 1997-12-02 | 2006-03-21 | Financial Engines | Identifying a recommended portfolio of financial products for an investor based upon financial products that are available to the investor |
| US7273887B1 (en) | 1999-10-22 | 2007-09-25 | Transdermatech, Inc. | Topical anesthetic formulation |
| US6673363B2 (en) | 1999-12-16 | 2004-01-06 | Dermatrends, Inc. | Transdermal and topical administration of local anesthetic agents using basic enhancers |
| US6455066B1 (en) | 2000-03-10 | 2002-09-24 | Epicept Corporation | Intradermal-penetration agents for topical local anesthetic administration |
| CN1284536C (zh) | 2000-09-18 | 2006-11-15 | 威克斯医药有限公司 | 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用 |
| CN1236773C (zh) | 2000-11-22 | 2006-01-18 | 南宁枫叶药业有限公司 | 用于镇痛、麻醉或治疗药物依赖性的制剂 |
| WO2002058670A1 (en) * | 2001-01-25 | 2002-08-01 | Euroceltique S.A. | Local anesthetic, and method of use |
| CN1382443A (zh) | 2001-04-25 | 2002-12-04 | 威克斯医疗仪器有限公司 | 钠离子通道阻断剂在制备用于局部神经麻醉或镇痛的药物中的应用 |
| HUP0402268A2 (hu) * | 2001-11-15 | 2005-02-28 | Micro Algae Corp. | 3,4-propinoperhidropurinokat tartalmazó gyógyászati kompozíciók és alkalmazásuk ingerületátvitel gátlására |
| WO2004050034A2 (en) | 2002-12-02 | 2004-06-17 | Massachusetts Institute Of Technology | Prolonged suppression of electrical activity in excitable tissues |
| US20040172354A1 (en) | 2003-02-13 | 2004-09-02 | Charnley James Allen | Calculator for illustrating investment performance for irregular time periods |
| WO2005079157A2 (en) | 2004-02-19 | 2005-09-01 | Dmitry Gorbatovsky | Portfolio optimization |
| US20050214325A1 (en) | 2004-03-26 | 2005-09-29 | Vvii Newco 2003, Inc. | Compositions and methods to increase the effect of a neurotoxin treatment |
| AU2005244096B2 (en) | 2004-05-07 | 2011-03-17 | Algenis Spa | Transdermal administration of phycotoxins |
| CN100367966C (zh) | 2004-09-28 | 2008-02-13 | 黄致强 | 河鲀毒素油相制剂的制备方法 |
| WO2006091719A2 (en) | 2005-02-23 | 2006-08-31 | Sontra Medical Corporation | Compositions and methods enhancing transdermal delivery of drugs and biologics |
| KR20140097446A (ko) | 2006-11-20 | 2014-08-06 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 통증 및 소양증 치료용 방법, 조성물 및 키트 |
| WO2009143175A2 (en) | 2008-05-19 | 2009-11-26 | Children's Medical Center Corporation | Sensory-specific local anesthesia and prolonged duration local anesthesia |
| US8658699B2 (en) | 2008-05-19 | 2014-02-25 | Massachusetts Institute Of Technology | Chemical permeation enhancers enhance nerve blockade by toxins |
| WO2010041255A2 (en) | 2008-10-07 | 2010-04-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Liposomal systems comprising sphingomyelin |
| CL2009000723A1 (es) | 2009-03-24 | 2009-06-19 | Proteus Sa | Metodo de purificacion industrial de ficotoxinas biologicamente activas que comprende proporcionar una cantidad adecuada de una fuente de ficotoxinas como por ejemplo el cultivo de un clon de cianobacterias. |
| CL2009000722A1 (es) | 2009-03-24 | 2009-06-19 | Proteus Sa | Metodo de obtención y producción masiva de una especie de cianobacteria aislada productora de ficotoxinas paralizantes, utilizando un medio de cultivo mla suplementado con arginina, metionina y ácido alantoico. |
| US20120034296A1 (en) | 2009-04-08 | 2012-02-09 | Massachusetts Institute Of Technology | Prolonged duration local anesthesia with minimal toxicity |
| US9174999B2 (en) | 2009-05-07 | 2015-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for studying, imaging, and treating pain |
| WO2011098539A1 (en) * | 2010-02-10 | 2011-08-18 | Phytotox Limited | Treatment of loss of sense of touch with saxitoxin derivatives |
| JP6313420B2 (ja) * | 2013-03-15 | 2018-04-18 | ザ チルドレンズ メディカル センター コーポレイション | 持続する局所麻酔のためのネオサキシトキシン併用製剤 |
-
2014
- 2014-03-17 JP JP2016503385A patent/JP6313420B2/ja active Active
- 2014-03-17 KR KR1020247009397A patent/KR102787826B1/ko active Active
- 2014-03-17 EP EP18215029.2A patent/EP3492075B1/en active Active
- 2014-03-17 PL PL14719486T patent/PL2968225T3/pl unknown
- 2014-03-17 CN CN201480015980.0A patent/CN105142625B/zh active Active
- 2014-03-17 CA CA2906851A patent/CA2906851C/en active Active
- 2014-03-17 US US14/216,252 patent/US10314833B2/en active Active
- 2014-03-17 PT PT14719486T patent/PT2968225T/pt unknown
- 2014-03-17 KR KR1020217012549A patent/KR20210062693A/ko not_active Ceased
- 2014-03-17 HU HUE14719486A patent/HUE042711T2/hu unknown
- 2014-03-17 AU AU2014232881A patent/AU2014232881B2/en active Active
- 2014-03-17 WO PCT/US2014/030372 patent/WO2014145580A1/en not_active Ceased
- 2014-03-17 SI SI201431117T patent/SI2968225T1/sl unknown
- 2014-03-17 PE PE2015002008A patent/PE20160011A1/es unknown
- 2014-03-17 ES ES14719486T patent/ES2727292T3/es active Active
- 2014-03-17 HR HRP20190419TT patent/HRP20190419T1/hr unknown
- 2014-03-17 CA CA3018668A patent/CA3018668C/en active Active
- 2014-03-17 ES ES18215029T patent/ES2972603T3/es active Active
- 2014-03-17 RU RU2015143665A patent/RU2015143665A/ru not_active Application Discontinuation
- 2014-03-17 DK DK14719486.4T patent/DK2968225T3/da active
- 2014-03-17 MX MX2015012879A patent/MX390159B/es unknown
- 2014-03-17 EP EP14719486.4A patent/EP2968225B1/en active Active
- 2014-03-17 KR KR1020157029781A patent/KR20150131330A/ko not_active Ceased
- 2014-03-17 RS RS20190594A patent/RS58750B1/sr unknown
- 2014-03-17 KR KR1020227032390A patent/KR20220132666A/ko not_active Ceased
- 2014-03-17 PL PL18215029.2T patent/PL3492075T3/pl unknown
- 2014-03-17 NZ NZ710890A patent/NZ710890A/en unknown
- 2014-03-17 LT LTEP14719486.4T patent/LT2968225T/lt unknown
- 2014-03-17 TR TR2019/03411T patent/TR201903411T4/tr unknown
- 2014-07-15 US US14/331,947 patent/US8975268B2/en active Active
- 2014-07-15 US US14/331,983 patent/US8975281B2/en active Active
-
2015
- 2015-09-09 CL CL2015002534A patent/CL2015002534A1/es unknown
- 2015-09-09 IL IL241346A patent/IL241346B/en active IP Right Grant
-
2017
- 2017-04-10 AU AU2017202343A patent/AU2017202343B2/en active Active
- 2017-11-24 RU RU2017141000A patent/RU2673081C1/ru active
-
2019
- 2019-04-16 CY CY20191100416T patent/CY1121606T1/el unknown
- 2019-04-26 US US16/396,071 patent/US10881647B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390159B (es) | Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada. | |
| CR20160170A (es) | Moduladores del factor del complemento b | |
| BR112014016805A2 (pt) | compostos terapeuticamente ativos e seus métodos de uso | |
| BR112016000561B8 (pt) | Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| CL2015003022A1 (es) | Uso de empagliflozina en la preparacion de un medicamento util en el tratamiento de la enfermedad renal cronica | |
| CL2015002941A1 (es) | Usos terapéuticos de empaglifozina | |
| BR112016002287A2 (pt) | compostos terapeuticamente ativos e seus métodos de uso | |
| MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| UA122324C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| TR201902516T4 (tr) | Glukagon-glp-1-gıp üçlü agonist bileşikleri. | |
| BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
| MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
| MX2015009058A (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
| BR112015023203A2 (pt) | métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos | |
| BR112012027197A2 (pt) | combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas | |
| HUE046671T2 (hu) | Glutárimid származékokat tartalmazó gyógyászati készítmény, valamint ennek alkalmazása eozinofil betegségek kezelésében | |
| BR112015017241A2 (pt) | doadores de nitroxil com índice terapêutico melhorado | |
| GT201600027A (es) | Inhibidores de rorc2 y sus métodos de uso | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| EA201591987A1 (ru) | Лечение злокачественной опухоли дигидропиразинопиразинами | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| MX387658B (es) | Métodos para tratar y/o prevenir queratosis actínica. | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina |